Literature DB >> 16439155

Right ventricular outflow tract reconstruction using Contegra valved conduit: natural history and conduit performance under pressure.

Suhair O Shebani1, Simon McGuirk, Max Baghai, John Stickley, Joseph V De Giovanni, Frances A Bu'lock, David J Barron, William J Brawn.   

Abstract

OBJECTIVE: To assess the performance of the bovine Contegra valved conduit used for right ventricular (RV) outflow tract reconstruction, particularly in relation to post-operative RV pressure.
METHODS: Follow-up study of 64 consecutive right ventricular to pulmonary artery-conduit implants in 62 patients between January 2000 and April 2003. The majority of cases were forms of pulmonary atresia/VSD (n=24, 39%) or Fallot's tetralogy (n=13, 21%). Thirteen cases (21%) had aortic atresia, truncus arteriosus or discordant connections with pulmonary atresia/VSD. Twelve cases (19%) were conduit replacements. Echocardiography was performed for a median follow-up of 14 months (range 0-38 months).
RESULTS: Median age at implantation was 13.8 months (range 0.1-244 months) and median weight was 8.9 kg (range 2.1-84.1 kg). Thirty-eight patients (59.4%) were <10 kg at the time of surgery. Early mortality was 6.4% (n=4). During follow-up there were four explantations (one for endocarditis and three for conduit dilatation) and 16 (28.6%) catheter interventions. Overall freedom from intervention at 1 and 3 years was 71+/-6% and 53+/-11%, respectively. Freedom from conduit-specific reintervention was 66+/-11% at the end of the study period. Reintervention was associated with small conduits (p=0.04), age <1 year (p=0.04) and with high RV/LV pressure ratio in the immediate post-operative period (p=0.0003). On multivariate analysis, the RV/LV pressure ratio was the strongest single factor predicting the overall reintervention (OR 5.45). Acquired distal conduit stenosis at suture line was the commonest indication for conduit-specific reintervention and was associated with the smaller conduits. The conduits explanted for dilatation showed neointimal proliferation, thrombosis, calcification and chronic inflammation.
CONCLUSIONS: The Contegra conduit is widely applicable to RVOT reconstruction with satisfactory mid-term results. However, there is a significant incidence of conduit-related complications, particularly with the smaller conduits. Adverse performance was strongly associated with high RV/LV pressure ratio at completion of surgery. We would recommend cautious use of the conduits in patients with predicted high RV/LV pressure ratios, where careful monitoring of conduit performance is crucial. There is some element of unpredictability, which adds to the importance of close follow-up. Further studies are needed to explore the issues of thrombogenicity, degeneration, possible 'rejection', and the potential role of anti-platelet and anti-inflammatory modulation.

Entities:  

Mesh:

Year:  2006        PMID: 16439155     DOI: 10.1016/j.ejcts.2005.11.040

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  12 in total

1.  Early clinical outcomes of right ventricular outflow tract reconstruction with small caliber bovine jugular vein conduit (Contegra®) in small children.

Authors:  Takashi Kido; Takaya Hoashi; Koji Kagisaki; Toshiki Fujiyoshi; Masataka Kitano; Kenichi Kurosaki; Isao Shiraishi; Toshikatsu Yagihara; Yoshiki Sawa; Hajime Ichikawa
Journal:  J Artif Organs       Date:  2016-05-28       Impact factor: 1.731

Review 2.  Current status of right ventricular outflow tract reconstruction: complete translation of a review article originally published in Kyobu Geka 2014;67:65-77.

Authors:  Yusuke Yamamoto; Masaaki Yamagishi; Takako Miyazaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-12-13

3.  Mid-term outcomes of Contegra implantation for the reconstruction of the right ventricular outflow tract to proximal branch pulmonary arteries: Japan multicentre study.

Authors:  Takaya Hoashi; Hajime Ichikawa; Keiichi Hirose; Naohiro Horio; Takahisa Sakurai; Hironori Matsuhisa; Yoshihiro Ohsima; Hajime Sakurai; Shingo Kasahara; Kisaburo Sakamoto
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-07-26

4.  Midterm results of homografts in pulmonary position: a retrospective single-center study.

Authors:  Javid Raja; Sabarinath Menon; Sowmya Ramanan; Sudip Dutta Baruah; Arun Gopalakrishnan; Baiju Sasi Dharan
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2020-11-23

5.  Long term results of right ventricular outflow tract reconstruction with homografts.

Authors:  Hye-Won Kim; Dong-Man Seo; Hong Ju Shin; Jeong-Jun Park; Tae-Jin Yoon
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2011-04-14

6.  The Contegra conduit: Late outcomes in right ventricular outflow tract reconstruction.

Authors:  Anthony A Holmes; Steve Co; Derek G Human; Jacques G Leblanc; Andrew Im Campbell
Journal:  Ann Pediatr Cardiol       Date:  2012-01

7.  Reconstruction of the pulmonary posterior wall using in situ autologous tissue for the treatment of pulmonary atresia with ventricular septal defect.

Authors:  Chengming Fan; Yifeng Yang; Lian Xiong; Ni Yin; Qin Wu; Mi Tang; Jinfu Yang
Journal:  J Cardiothorac Surg       Date:  2017-02-23       Impact factor: 1.637

8.  MRSA endocarditis of bovine Contegra valved conduit: a case report.

Authors:  Gani Bajraktari; Rozafa Olloni; Irfan Daullxhiu; Fadil Ademaj; Zana Vela; Mubekir Pajaziti
Journal:  Cases J       Date:  2009-01-15

Review 9.  Contegra conduit for reconstruction of the right ventricular outflow tract: a review of published early and mid-time results.

Authors:  Aristotle D Protopapas; Thanos Athanasiou
Journal:  J Cardiothorac Surg       Date:  2008-11-18       Impact factor: 1.637

10.  Pulmonary valve replacement after right ventricular outflow tract reconstruction with homograft vs Contegra®: a case control comparison of mortality and morbidity.

Authors:  Nicolas Poinot; Jean-Francois Fils; Hélène Demanet; Hugues Dessy; Dominique Biarent; Pierre Wauthy
Journal:  J Cardiothorac Surg       Date:  2018-01-17       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.